Related Experiment Video
Updated: Jun 23, 2026
11:34
Murine Lymphocyte Labeling by 64Cu-Antibody Receptor Targeting for In Vivo Cell Trafficking by PET/CT
Published on: April 29, 2017
PET/CT for therapy response assessment in lymphoma
Martin Hutchings1, Sally F Barrington
1Department of Oncology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark. hutchings@dadlnet.dk
Summary
Fluorodeoxyglucose F 18 (18F-FDG) PET scans are vital for staging and prognosis in Hodgkin lymphoma (HL) and aggressive non-Hodgkin lymphoma (NHL). Further trials are needed to confirm the benefit of interim (18F-FDG) PET in improving patient outcomes.
Area of Science:
- Nuclear medicine
- Oncology
- Radiology
Background:
- Fluorodeoxyglucose F 18 (18F-FDG) Positron Emission Tomography (PET) is a standard staging tool for most lymphoma subtypes.
- Interim and end-of-treatment (18F-FDG) PET scans provide high prognostic value in Hodgkin lymphoma (HL) and aggressive non-Hodgkin lymphoma (NHL), correlating with patient survival.
- (18F-FDG) PET is integrated into revised response criteria for aggressive lymphomas, with ongoing trials exploring treatment adaptation based on early scan results.
Purpose of the Study:
- To evaluate the prognostic significance and clinical utility of (18F-FDG) PET in lymphoma management.
- To assess the role of (18F-FDG) PET in treatment monitoring for both aggressive and indolent lymphomas.
- To highlight the need for standardized guidelines for interpreting and reporting (18F-FDG) PET response monitoring scans.
Main Methods:
- Review of current literature and clinical practice regarding the use of (18F-FDG) PET in lymphoma.
- Analysis of the prognostic value of (18F-FDG) PET in Hodgkin lymphoma and aggressive non-Hodgkin lymphoma during and after therapy.
- Examination of evidence supporting (or refuting) the use of (18F-FDG) PET for indolent lymphomas and surveillance.
Main Results:
- (18F-FDG) PET demonstrates high prognostic value and survival correlation in HL and aggressive NHL.
- Limited evidence supports (18F-FDG) PET for monitoring indolent lymphomas or routine surveillance.
- Ongoing trials investigate treatment adaptation based on early (18F-FDG) PET results in HL and aggressive NHL.
Conclusions:
- While (18F-FDG) PET is crucial for staging and prognosis in aggressive lymphomas, its role in indolent lymphoma monitoring and surveillance is not well-established.
- Standardized, evidence-based guidelines are necessary for consistent interpretation and reporting of (18F-FDG) PET scans to facilitate clinical practice and trial comparisons.
- Further well-designed clinical trials are recommended to definitively assess whether interim (18F-FDG) PET improves patient outcomes.
